ERCC2 and cancer: XPD gene polymorphism at position 751 in exon 23 (rs13181) resulting in a lysine-to-glutamine transition, may alter the interactions of different proteins, reduce the activity of TFIIH complexes and modulate the genetic susceptibility for cancer.